Alkem Laboratories Ltd (ALKEM) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 64553.14 Cr. Figures below are as reported and are shown with their source and date.
Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,871 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The firm operates through a segment, Pharmaceuticals. The company has approximately 21 manufacturing facilities at multiple locations in India and the United States. The firm has approximately 800 brands and operates in 40 countries.
Source: finedge · as of 2026-09-29
Last close (₹): 5,013.5
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 14,712.27 | 2,301.8 | 192.51 |
| Mar 2025 | 12,964.52 | 2,165.48 | 181.11 |
| Mar 2024 | 12,667.58 | 1,795.77 | 150.19 |
| Mar 2023 | 11,599.26 | 984.17 | 82.31 |
| Mar 2022 | 10,634.19 | 1,645.62 | 137.63 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Source: nse · as of 2026-10-05
Figures computed 2026-10-23.